Capillary leak syndrome and aseptic meningitis in a patient with Kawasaki disease

Abstract Background Capillary leak syndrome (CLS) is a rare disease characterized by profound vascular leakage and presents as a classic triad of hypotension, hypoalbuminemia and hemoconcentration. Severe CLS is mostly induced by sepsis and generally life-threatening in newborns, especially in premature infants. Continuous renal replacement therapy (CRRT) plays an important role of supportive treatment for severe CLS. Unfortunately, CRRT in preterm infants has rarely been well defined. Case presentation We report the case of a 11-day-old girl with CLS caused by sepsis, who was delivered by spontaneous vaginal delivery (SVD) at gestational age of 25 weeks and 4 days, and a birth weight of 0.89 Kilograms(kg). The infant received powerful management consisting of united antibiotics, mechanical ventilation, intravenous albumin and hydroxyethyl starch infusion, vasoactive agents, small doses of glucocorticoids and other supportive treatments. However, the condition rapidly worsened with systemic edema, hypotension, pulmonary exudation, hypoxemia and anuria in about 40 h. Finally, we made great efforts to perform CRRT for her. Fortunately, the condition improved after 82 h’ CRRT, and the newborn was rescued and gradually recovered. Conclusion CRRT is an effective rescue therapeutic option for severe CLS and can be successfully applied even in extremely-low-birth-weight premature.

Download Full-text

Capillary Leak Syndrome Likely the Result of Granulocyte Colony-Stimulating Factor after High-Dose Chemotherapy.

Internal Medicine ◽

10.2169/internalmedicine.33.115 ◽

1994 ◽

Vol 33 (2) ◽

pp. 115-119 ◽

Cited By ~ 27

Author(s):

Eiichi OEDA ◽

Kenji SHINOHARA ◽

Shinji KAMEI ◽

Jun NOMIYAMA ◽

Hirofumi INOUE

Keyword(s):

High Dose Chemotherapy ◽

Capillary Leak Syndrome ◽

High Dose ◽

Granulocyte Colony Stimulating Factor ◽

Capillary Leak ◽

Colony Stimulating Factor ◽

Stimulating Factor

Download Full-text

Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)

Blood ◽

10.1182/blood-2011-08-375816 ◽

2012 ◽

Vol 119 (18) ◽

pp. 4321-4332 ◽

Cited By ~ 89

Author(s):

Zhihui Xie ◽

Chandra C. Ghosh ◽

Roshni Patel ◽

Shoko Iwaki ◽

Donna Gaskins ◽

...

Keyword(s):

Clinical Symptoms ◽

Case Series ◽

Fiber Formation ◽

Capillary Leak Syndrome ◽

Actin Stress Fiber ◽

Vascular Endothelial ◽

Capillary Leak ◽

Systemic Capillary Leak Syndrome ◽

Humoral Factors ◽

Clarkson Disease

Abstract The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.

Download Full-text

Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment

Immunotherapy ◽

10.2217/imt-2020-0332 ◽

2021 ◽

Author(s):

Ruth Percik ◽

Asher Nethanel ◽

Yair Liel

Keyword(s):

Adverse Effect ◽

Immune Response ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Endothelial Damage ◽

Capillary Leak Syndrome ◽

Capillary Leak ◽

Cytokine Activation ◽

Complex Interactions ◽

Cellular Immune

Capillary-leak syndrome is strongly associated with cytokine activity states. It is an ill-recognized adverse effect of checkpoint inhibitors treatment, which are typically associated with cellular immune response. We describe two patients with capillary leak syndrome following immune checkpoint inhibitors treatment. We present linking mechanisms between checkpoint inhibitors, cellular immunity, cytokine action and endothelial damage. We suggest that capillary-leak syndrome is a unique adverse effect of immunotherapy, resulting from complex interactions between cellular and cytokine activation and that its expression is probably depending on inherent host immune variabilities.

Download Full-text

Encephalopathy Due to Capillary Leak Syndrome

Southern Medical Journal ◽

10.1097/00007611-199710000-00020 ◽

1997 ◽

Vol 90 (10) ◽

pp. 1060-1062 ◽

Cited By ~ 10

Author(s):

TULIO E. BERTORINI ◽

MICHAEL S. GELFAND ◽

THOMAS F. OʼBRIEN

Keyword(s):

Capillary Leak Syndrome ◽

Capillary Leak

Download Full-text